Abstract
Particulate structures hold great promise for the development of effective and affordable recombinant prophylactic as well as therapeutic vaccines. Different types of particulate structures, including virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune response (humoral vs cellular) to be elicited. Particulate structures allow the insertion or fusion of foreign antigenic sequences, resulting in chimeric particles delivering foreign antigens on their surface. Similarly, they are used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. Particulate structures, indeed, represent a very efficient system for delivering antigens to antigen presenting cells (APC) which, in turn, trigger and amplify the adaptive immune response. The present review will address the biological and immunological properties of particulate structures, in particular VLPs, as platform for vaccine development.
Keywords: Virus-like particles, vaccine, antigen-presenting cells, HIV, innate immunity, adaptive immunity
Current HIV Research
Title: Virus-Like Particles as Particulate Vaccines
Volume: 8 Issue: 4
Author(s): Luigi Buonaguro, Maria L. Tornesello and Franco M. Buonaguro
Affiliation:
Keywords: Virus-like particles, vaccine, antigen-presenting cells, HIV, innate immunity, adaptive immunity
Abstract: Particulate structures hold great promise for the development of effective and affordable recombinant prophylactic as well as therapeutic vaccines. Different types of particulate structures, including virus-like particles (VLPs) and virosomes, have been developed depending on the nature of the viral pathogen to be targeted and the type of immune response (humoral vs cellular) to be elicited. Particulate structures allow the insertion or fusion of foreign antigenic sequences, resulting in chimeric particles delivering foreign antigens on their surface. Similarly, they are used as carriers for foreign antigens, including non-protein antigens, via chemical conjugation. Particulate structures, indeed, represent a very efficient system for delivering antigens to antigen presenting cells (APC) which, in turn, trigger and amplify the adaptive immune response. The present review will address the biological and immunological properties of particulate structures, in particular VLPs, as platform for vaccine development.
Export Options
About this article
Cite this article as:
Buonaguro Luigi, L. Tornesello Maria and M. Buonaguro Franco, Virus-Like Particles as Particulate Vaccines, Current HIV Research 2010; 8 (4) . https://dx.doi.org/10.2174/157016210791208659
DOI https://dx.doi.org/10.2174/157016210791208659 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Current Medicinal Chemistry Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Current Topics in Medicinal Chemistry Iron Chelators in Cancer Chemotherapy
Current Topics in Medicinal Chemistry Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Subject Index To Volume 13
Current Medicinal Chemistry A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology The Immunomodulatory Potential of Selected Bioactive Plant-Based Compounds in Breast Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targets for Metastatic Prostate Cancer
Current Drug Targets Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma
Anti-Cancer Agents in Medicinal Chemistry Killing Glioma ‘Stem-like’ Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins
Anti-Cancer Agents in Medicinal Chemistry Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Effect of SDF-1 α on Endogenous Mobilized and Transplanted Stem Cells in Regeneration after Myocardial Infarction
Current Pharmaceutical Design The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research A Natural Membrane Vesicle Exosome-based Sinomenine Delivery Platform for Hepatic Carcinoma Therapy
Current Topics in Medicinal Chemistry Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry